DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a medical device company focused on infectious disease and dermatology, today announced that preclinical testing of a silicone medical device incorporating the Company’s CeraShield™ antimicrobial technology has achieved 200 days of continuous antimicrobial efficacy. The prototype device being tested is an intravaginal silicone ring. Antimicrobial intravaginal rings may be of potential benefit in preventing transmission of certain sexually transmitted diseases. The Company had previously announced when it had achieved 120 days of continuous efficacy in the same study.
